Literature DB >> 17019419

Orbital inflammatory disease: a diagnostic and therapeutic challenge.

L K Gordon1.   

Abstract

The spectrum of orbital inflammatory disease (OID) ranges broadly from specific disease diagnoses, for example, Wegener's granulomatosis or sarcoidosis, to nonspecific inflammation which may involve one or multiple structures of the orbit. Mimics of idiopathic OID must be considered in a comprehensive differential diagnosis and include malignancies, congenital mass lesions, infectious diseases, and occult or distant trauma. Idiopathic OID may be secondary to an underlying systemic inflammatory disease, which must be diagnosed in order to develop a comprehensive therapeutic plan, or may represent localized pathologic processes without systemic involvement. Evaluation of the patient with suspected OID must include a careful history, physical examination, directed laboratory, and radiologic studies, and may sometimes require tissue for diagnostic studies. Therapeutic options for inflammatory diseases are expanding as biologically targeted agents become available that act on specific segments of the inflammatory cascades. The purpose of this paper is to provide a framework for the evaluation and management of patients with the spectrum of diseases known as OID and to discuss some of the new advances in immunologic monitoring and targeted immune therapies that will likely play an increasingly important role in the care of these patients.

Entities:  

Mesh:

Year:  2006        PMID: 17019419     DOI: 10.1038/sj.eye.6702383

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  37 in total

Review 1.  Systemic immunoglobulin G4 (IgG4) disease and idiopathic orbital inflammation; removing 'idiopathic' from the nomenclature?

Authors:  D Lindfield; K Attfield; A McElvanney
Journal:  Eye (Lond)       Date:  2012-02-03       Impact factor: 3.775

2.  Factors associated with multiple recurrences of nonspecific orbital inflammation aka orbital pseudotumor.

Authors:  Puneet S Braich; Robin K Kuriakose; Naveen S Khokhar; Jared C Donaldson; Timothy J McCulley
Journal:  Int Ophthalmol       Date:  2017-06-20       Impact factor: 2.031

3.  Cyclical orbital eosinophilic myositis.

Authors:  Mahiul M K Muqit; Robert H Taylor
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

4.  Tolosa-Hunt syndrome responsive to infliximab therapy.

Authors:  Ged O' Connor; Michael Hutchinson
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 5.  Orbital and anterior visual pathway infection and inflammation.

Authors:  Roel De Wyngaert; Ingele Casteels; Philippe Demaerel
Journal:  Neuroradiology       Date:  2009-02-17       Impact factor: 2.804

6.  Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors:  Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

7.  Unilateral proptosis in a woman with asthma.

Authors:  Saori Sakaue; Shuji Sumitomo; Keishi Fujio; Kazuhiko Yamamoto
Journal:  BMJ Case Rep       Date:  2015-02-12

Review 8.  "Orbiting around" the orbital myositis: clinical features, differential diagnosis and therapy.

Authors:  F Montagnese; S Wenninger; B Schoser
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 9.  Orbital inflammatory disease: Pictorial review and differential diagnosis.

Authors:  Michael N Pakdaman; Ali R Sepahdari; Sahar M Elkhamary
Journal:  World J Radiol       Date:  2014-04-28

10.  Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation.

Authors:  Brian J Lee; Stephen Atkins; Anna Ginter; Victor M Elner; Christine C Nelson; Raymond S Douglas
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 May-Jun       Impact factor: 1.746

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.